infection (CA-CDI; defined as cases without prior hospitalization in the previous 12 weeks who were either tested outside of hospital or tested within 2 days of admission to hospital) is a major public health problem. This study estimates the magnitude of the association between temporal and cumulative prescribing of antimicrobials in primary care and CA-CDI.
Introduction
Clostridium difficile infection (CDI) is a major public health problem and a key focus for antimicrobial stewardship programmes. Quantification of the adverse effects of antimicrobial use at population level is essential to support appropriate antimicrobial stewardship policy. Community-associated (CA)-CDI is an increasing public health threat, 1 studies indicating that 37%-79% of cases have had antimicrobial exposure in the preceding 90 days. [2] [3] [4] [5] [6] [7] A meta-analysis 8 derived pooled ORs from eight studies for the risk of CA-CDI associated with specific antimicrobial groups, but did not consider cumulative or temporal exposure effects. Cumulative and temporal antimicrobial exposures have been examined in healthcare-associated CDI (HA-CDI), [9] [10] [11] but for CA-CDI data are limited to considering the cumulative effect in an elderly population 12 and considering temporal effects for overall antimicrobial exposure only, 13 with both studies limited to low CA-CDI numbers. The increasing availability of routinely captured electronic administrative health data, readily linkable through use of unique patient identifiers, affords the opportunity to examine complex patterns of drug use over time at population level. This supports the derivation of more accurate estimates of risk, providing clinicians and policy-makers with information that can be used to improve patient treatment and minimize harm at individual and population level. The aim of our study was to use nationally collected routine healthcare data to estimate associations between CA-CDI and prior prescription of antimicrobials in primary care, considering exposure to (i) any antimicrobial and (ii) specific broad-spectrum antimicrobials. We examined the effects of any exposure and cumulative exposure, and the temporal relationship between timing of antimicrobial exposure and risk of CA-CDI.
Methods

Data sources
Three National Health Service (NHS) patient-level datasets-Electronic Communication of Surveillance in Scotland (ECOSS), Prescribing Information System (PIS) and General/Acute and Inpatient Day Case dataset (SMR01), all indexed by the NHS Scotland unique patient identifier Community Health Index (CHI)-are linked as part of the Infection Intelligence Platform (IIP), 14 allowing generation of the study dataset. The CHI register for Scotland was used for control assignment. The NHS in Scotland has universal coverage so all data, including prescribing, 15 are representative of the whole population.
ECOSS records all positive C. difficile tests from NHS laboratories in Scotland through mandatory reporting, with standardization of sampling, testing and reporting across all clinical settings. All diarrhoeal samples are tested in a two-step algorithm, firstly identifying the presence of C. difficile using glutamate dehydrogenase screening, and secondly identifying the presence of toxin using ELISA/PCR. Health Protection Scotland (HPS) then validates with the NHS health boards which positive tests represent individual, clinically symptomatic CDI episodes (toxin positive and patient has experienced diarrhoea not attributable to any other cause). PIS records all prescriptions dispensed and reimbursed within primary care in Scotland. SMR01 contains episode-level data on all hospital inpatient and day-case discharges from hospitals in Scotland. 16 
Data linkage and control assignment
All validated CDI cases with test date from August 2010 to July 2013 were extracted from ECOSS and linked to hospitalization histories from SMR01. CA cases were defined as those without prior hospitalization in the previous 12 weeks and were either tested outside of hospital [community onset (CO)] or tested within 48 h (2 days) of admission to hospital [healthcare onset (HO)]. 17 CA-CDI cases were assigned up to six community-based controls from the CHI register for Scotland, matched on age (within 5 years), gender and location (intermediate zone derived from the patient's postcode). For the CA-HO cases, hospital-based controls were additionally assigned: up to six controls were selected from hospitalized individuals without CDI admitted to the same hospital within 7 days of the CDI case's admission date and who were still in hospital on the case's CDI test date.
For all cases and controls, prescription records from August 2009 from PIS were linked, allowing assignment of antimicrobial, proton pump inhibitor (PPI) and H2 antagonist exposure in the 6 months prior to CDI test date, and construction of comorbidity measures. Antimicrobial (for this study defined as any systemic antibacterial) exposure was defined as any exposure (present/absent), temporal exposure (how long prior to the test date the antimicrobial was prescribed) and cumulative exposure (in WHO ATC DDDs), 18 cumulating potentially multiple prescriptions in the previous 6 months.
The prescribing measures of comorbidity were counts of the total number of prescriptions and the total number of different prescribed drugs (based on approved name) in the previous year. In addition, 5 years of hospitalization records were used to construct a Charlson index of comorbidity for all cases and controls based on ICD-10 diagnosis discharge codes. 19 Individuals with no hospitalizations in the previous 5 years were assigned an 'unknown' Charlson index to differentiate them from individuals with a hospitalization and no recorded comorbidities, who were assigned a score of 0. Scottish Index of Multiple Deprivation (SIMD) quintiles, a measure of socioeconomic status that incorporates different aspects of deprivation into a single index, care home residence (yes/no) and NHS health board from the CHI register, were assigned to all records.
All linkage was via CHI and case/control assignment was performed by the electronic Data Research and Innovation Service at NSS Information Services Division. No patient identifiers were available to the study team and all data were accessed via the National Safe Haven.
Ethics
Ethics permission for this study was not required as it used only nonidentifiable routine data. Approval for the study was granted by the NHS National Services Scotland Privacy Advisory Committee (study number XRB13122).
Statistical analysis
Associations between antimicrobial exposure and CDI were assessed using conditional logistic regression. The distribution of potential confounding variables (previous hospital admissions, prescription totals, comorbidity score, care home residency status, PPI/H2 antagonist exposure and SIMD) was investigated in the cases and controls and adjusted for in the analysis. Four antimicrobial exposure groupings were examined: (i) any antimicrobials; (ii) a predefined broad-spectrum, high-risk '4C' group 12 [clindamycin, cephalosporins, co-amoxiclav and the fluoroquinolones (ciprofloxacin, which accounts for .90% of all fluoroquinolone prescriptions in Scotland, levofloxacin, moxifloxacin, norfloxacin and ofloxacin)]; (iii) fluoroquinolones only; and (iv) all 'non-4C' antimicrobials. Interaction tests were used to investigate whether the effects of antimicrobial prescribing were the same in those prescribed a PPI.
Sensitivity analyses examined the effect of restricting the definition of CA-CDI to cases with no hospitalization in the previous 6 and 12 months. We also provided stratified results for HO cases matched to both population and hospital-based controls. All analysis was conducted using R version 3.2.1.
Results
Between 1 August 2010 and 31 July 2013 there were 6019 confirmed CDI episodes in Scotland, of which 1612 (26.8%) were CA-CDI. Of these, 1557 were successfully assigned populationbased controls (Figure 1 ). For the patients with more than one CA-CDI episode a single episode was randomly selected, resulting in a sample of 1446 cases with 7964 matched controls.
Cases were more likely to have been in hospital in the previous year (43.0% versus 14.0%) and exposed to PPIs (41.8% versus 22.4%), and had more comorbidity by both prescribing measures and Charlson index (Table 1) . Crude odds of CA-CDI were higher with higher comorbidity scores (Charlson index 4 versus 0; OR " 4.2, 95% CI 2.5-7.0), with any hospital admission in the previous year (OR " 4.9, 95% CI 4.3-5.6) and with PPI or H2 antagonist exposure (Table 2 ). After adjustment, the scale of these effects diminished, but previous hospital admission (OR " 2.15, 95% CI 1.8-2.6), higher Charlson index and H2 antagonist exposure remained significant, but PPI exposure did not (Table 2) .
Among cases, 58.7% were exposed to any antimicrobial in the previous 6 months compared with 23.0% of controls. After adjustment, the odds of CA-CDI after any antimicrobial exposure was 2.8 (95% CI 2.4-3.2) compared with no antimicrobial exposure ( Figure 2 and Table 2 ). Adjusted odds of CA-CDI were Kavanagh et al.
even higher for prior exposure to 4C (OR " 6.1, 95% CI 4.8-7.7) and fluoroquinolone (OR " 5.4, 95% CI 3.8-7.8) antimicrobials.
PPI exposure was common (Table 1) and significantly modified the effect of antimicrobial exposure (interaction test P " 0.0001). Of the cases, 26.7% were exposed to neither PPIs nor antimicrobials, 31.5% to only antimicrobials (OR " 3.4, 95% CI 2.8-4.1, for CA-CDI), 14.6% to only PPIs (OR " 1.38, 95% CI 1.1-1.7) and 27.3% to both (OR " 2.7, 95% CI 2.1-3.4). Two hundred and thirty-one (16%) CA-CDI cases had no antimicrobial, PPI or H2 antagonist exposure, Charlson index 0 and no previous hospitalizations.
Sensitivity analysis to extend the exclusion period for prior hospitalization from 12 weeks to 6 months led to marginally higher associations, but little further change when using a 12 month exclusion. All CIs overlapped with the baseline results (4C exclusion 6 months, OR " 7.4, 95% CI 5.6-9.7; 12 month exclusion, OR " 7.1, 95% CI 4.9-10.3). Considering the subset of CA-CDI cases with HO, similar effect sizes were found for this group when matched to population-based controls (Table 3 ). Matching to hospital-based controls reduced the associations found: any antimicrobial exposure had an odds of CDI of 1.5 (95% CI 1.2-2.0) compared with no exposure and 4C exposure gave an increased odds of 2.17 (95% CI 1.5-3.3).
Cumulative antimicrobial exposure was high, with 19.9% of cases having 29! DDDs in 6 months. Compared with no exposure, up to 7 DDDs of any antimicrobial gave odds of CA-CDI of 2.3 (95% CI 1.9-2.9) compared with 4.4 (95% CI 3.4-5.6) for 29! DDDs Association between antimicrobials and CDI JAC (Table 4 ). 4C exposure duration was typically short among controls, but more variable among cases. Among cases, 3.3% had 29! DDDs of 4C antimicrobials, which had associated odds of CDI of 17.9 (95% CI 7.6-42.2) compared with 4.6 (95% CI 3.4-6.2) for 1-7 DDDs, with a similar pattern for cumulative fluoroquinolone exposure (Table 4) . Increasing durations of non-4C antimicrobials increased CA-CDI risk, with OR for 29! DDDs of 3.9 (95% CI 3.0-5.1), which is about half the OR for 29! DDDs of 4C exposure (6.4; 95% CI 4.6-8.9).
Among the 287 cases with 29! DDD exposure, the pattern of antimicrobial prescribing was complex and more consistent with repeated short treatment course prescriptions than long-term prophylaxis ( Figure S1 and Table S1 , available as Supplementary data at JAC Online). The most commonly prescribed antimicrobials were amoxicillin, trimethoprim, flucloxacillin, co-amoxiclav, ciprofloxacin and nitrofurantoin, each of which was prescribed to at least 20% of the 287 patients (Table S2) .
Time since most recent antimicrobial treatment had a significant impact on CDI risk (Table 5) . Considering any antimicrobial, the effect was strongest in those exposed in the previous 4 weeks (OR " 6.3, 95% CI 5.2-7.7) compared with exposure 2-3 months earlier (OR " 2.2, 95% CI 1.8-2.7). By 4-6 months the effect of any exposure was lost (OR " 1.1, 95% CI 0.9-1.4), with a similar pattern observed for non-4C antimicrobials. Exposure to 4C antimicrobials within the previous month increased the OR of CDI to 12.5 (95% CI 8.9-17.4), decreasing to 5.1 (95% CI 3.5-7.5) by 2-3 months post-exposure. The effects for both 4C and fluoroquinolones were still significant 4-6 months postexposure (4C, OR " 2.6, 95% CI 1.7-3.9).
Discussion
In this whole-population study we linked validated CDI cases to administrative datasets to quantify the risk of CA-CDI associated with community antimicrobial exposure. Any antimicrobial exposure within the previous 6 months increased the risk, with elevated risk remaining for up to 3 months. We found larger associations with high-risk antimicrobials and found even higher effects of cumulative exposure among this group and effects persisting up to 6 months following exposure.
Our study established that 58.7% of CA-CDI cases had been exposed to an antimicrobial in the preceding 6 months, not dissimilar to other studies. [2] [3] [4] [5] [6] [7] A recent meta-analysis, including studies with significant heterogeneity and covering an earlier time frame, 8 reported a higher OR for exposure to any antimicrobial (7.3, 95% CI 4.3-12.6) compared with 2.8 in our study. 
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Antimicrobial prescribing has changed over time, particularly in Scotland, in response to high rates and outbreaks of CDI in 2007/ 08. 20 The antimicrobial with the strongest association with CA-CDI in the meta-analysis, 8 clindamycin, was used very rarely in our study population [2.1% (31/1446) of cases and 0.03% (2/7964) controls had exposure in the previous 6 months], and reduced prescribing of the whole 4C group has been successfully targeted in Scotland. 21 Consistent with this, our estimates are also lower than those reported by Marwick et al. 12 The case-control component of this study focused only on elderly individuals in a single region of Scotland (n " 62 cases, 620 controls). Restricting our analysis to the same age group and geography yields similar estimates, though the CIs become wide due to the small sample size (Table  S3) .
Cumulative total exposure to any antimicrobial has been clearly demonstrated to increase HA-CDI risk, 9-11 but evidence in CA-CDI is sparse. Marwick et al. 12 found a dose-response relationship, with the OR for CDI increasing from 2.9 (95% CI 1.2-6.7) for 1-7 days of exposure to 12.7 (95% CI 5.2-31.3) for 29! days of exposure-a higher magnitude than in our study. This may partly reflect our inclusion of the entire population rather than only the elderly, who are known to be at higher risk of CDI. It may also be attributable to our classification of cumulative exposure as DDDs rather than days of therapy derived from prescription directions.
There is little published evidence, even for HA-CDI, of the incremental impact of cumulative exposure of different groups of antimicrobials. Marwick et al.
12 generated ORs for cumulative 4C antimicrobials, but the small sample size prevented meaningful subgroup analysis. Our inclusion of the whole population with confirmed CA-CDI in Scotland over a 3 year period enabled subanalysis by antimicrobial group. We demonstrate clear increasing odds of CA-CDI with increasing cumulative exposure to antimicrobials, particularly for the 4C antimicrobial subgroup. For fluoroquinolones, the dose-response relationship remained, but there was higher variability surrounding the estimates, due to reducing prescription numbers.
We found a high proportion (29.9%) of CA-CDI cases had received 29! DDDs of antimicrobial in the 6 months prior to CDI. This included prescribing consistent with planned long-term use for urinary tract infection prophylaxis (nitrofurantoin, trimethoprim) and skin conditions (flucloxacillin, doxycycline), as may be expected, but the majority of cases involved various antimicrobials, including ciprofloxacin, co-amoxiclav and amoxicillin, and the number of prescriptions and DDDs per prescription was more consistent with multiple short treatment courses. This prescribing pattern was unexpected and represents potentially avoidable, highrisk antimicrobial prescribing and an important message for primary care prescribers.
The period of increased risk of CDI following antimicrobial use remains an important clinical question. Previous studies have mainly examined and found an increased risk associated with CA-CDI up to 3 months after antimicrobial use. 3, 13, 22 This has been affirmed in our study and is also similar to the risk observed in HA-CDI Association between antimicrobials and CDI JAC studies. 10, 11 One study 13 examined prior antimicrobial use up to 180 days and found the increased risk remained up to 150 days (OR " 2.8, 95% CI 1.3-6.0) then returned to baseline. In our study the period of elevated risk for any antimicrobials remained up to 3 months, but was lost by 4-6 months, although it was still elevated for 4C and fluoroquinolone antimicrobials. This differential temporal impact of antimicrobial groups up to 6 months is an important finding to support antimicrobial stewardship initiatives and the development of clinical decision support tools.
The unadjusted effect of PPI prescribing was similar to that reported by a previous meta-analysis, 22 but the effect diminished with covariate adjustment. The meta-analysis 22 estimated a pooled OR of 1.93 for the association between PPI exposure and CDI, but only three of 29 included studies involved CA-CDI, with effect sizes of OR " 0.9, 23 OR " 2.9 24 and OR " 3.5, 2 with each having differing case and exposure definitions. Whilst the effect of PPI exposure was diminished with covariate adjustment, the effect of H2 antagonists remained significant (OR " 1.4). This may be due to Table 3 . Odds of CDI, together with 95% CIs, given antibiotic exposure for CA-HO cases matched to both population-based and hospital-based controls Exposure CA-HO n " 476 a matched to populationbased controls n " 2581, adjusted OR (95% CI)
CA-HO n " 476 a matched to hospitalbased controls n " 957, adjusted OR (95% CI) Number of HO cases reduces to n " 476 when considering the cases that have both population-and hospital-based controls assigned to them.
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residual confounding, potentially attributable to prescription of H2 antagonists in preference to PPIs in patients who are deemed to be at a higher risk of CDI. After covariate adjustment, in particular adjustment for comorbidities (Charlson index and overall prescription counts), and accounting for antimicrobial prescribing, the effect of care home residence on CA-CDI became insignificant. This effect was lower than in the study of Marwick et al., 12 which found a significant adjusted association with care home residence (OR " 4.1, 95% CI 1.7-9.6); however, this study did not adjust for Charlson index. Using the inclusion criteria and adjusting factors described by Marwick et al., 12 analysis of our data gave a non-significant adjusted OR for care home residence of OR " 2.2 (95% CI 0.8-5.7), but similar effect sizes for cumulative antimicrobial prescribing, PPI exposure and total prescriptions in the previous year. The study by Marwick et al. 12 and the present study took place at different times (from November 2008 to October 2009 and from 2010 to 2013, respectively), suggesting a reduction in the residual care home effect in the latter period, perhaps attributable to improved stewardship over this time period. 20 This study illustrated that a sizeable proportion (16%) of individuals had not been exposed to PPIs, H2 antagonists or antimicrobials, had not been an inpatient in the previous year and had no comorbidities recorded, indicating a significant proportion of CA-CDI cases that have not been exposed to the classically understood risk factors. These individuals were a younger subset of the Models are adjusted for SIMD, Charlson index, any hospitalization in the previous year y/n, total number of prescriptions in the previous year, total number of different prescriptions, care home residence, and PPI and H2 antagonist exposure. In the exposure categories for 4C antibiotics individuals may be exposed to non-4C antibiotics as well. In the exposure categories for non-4C antibiotics individuals may be exposed to 4C antibiotics as well. In the exposure categories for fluoroquinolone antibiotics individuals may be exposed to non-fluoroquinolone antibiotics as well.
a To calculate DDD exposure, both quantity and a scaling factor representing the recommended daily dose are required. For five observations either or both of these were missing for the antimicrobial exposure variable. One was missing for the fluoroquinolone and 4C exposure. These observations are excluded from the analysis.
Association between antimicrobials and CDI JAC cases (median age 48), but have a considerably higher number of community prescriptions than their matched controls, indicating comorbidities not serious enough to require hospitalization, hence not captured in the routinely used Charlson index. We believe the data in our study to be robust and have high levels of completeness. Reporting of CDI is mandatory and all cases used in our analysis are validated. SMR01 covers all residents in Scotland that receive care in hospital, enabling robust classification of CA disease. Antimicrobial exposure is assessed via an individual's prescriptions dispensed in the community, which can be robustly measured, 15 and during the study period CHI completeness of the prescription data was between 94% and 96%.
The main data limitation, which impacts on our CA-HO subanalysis, is the lack of routine patient-level information on hospital prescribing, which is not presently captured electronically in Scotland. The effect of this is mitigated to some extent because the CA-CDI definition excludes those with a hospitalization in the previous 12 weeks, and our sensitivity analysis showed only a marginal impact of extending the period for no prior hospitalization to 12 months. It does, however, hinder the generalizability of this methodology to the examination of HA-CDI.
A further limitation, common to all observational studies of medication effects, is the inability to measure adherence, and it is known that adherence to antimicrobials in the community is variable. Using dispensed prescribing data, as we have, is better in this regard than using datasets based on prescriptions generated.
Our findings have important implications for antimicrobial prescribing decisions in primary care, and for prescribing guidelines, emphasizing that all exposure in the previous 6 months influences the risk versus benefit of prescribing any antimicrobial and specific antimicrobials. A significant number of patients in our study were at continually high CDI risk. The next phase of research should apply such routine data in cohort studies to derive clinical risk prediction scores and numbers needed to harm, to definitively quantify risk to help frontline clinicians to improve patient-centred, safe and effective antimicrobial stewardship.
In conclusion, this is the largest study to assess the impact of duration and time since antimicrobial therapy on CA-CDI and demonstrates that antimicrobial exposure had a clear dose-response relationship, with the odds of CDI more than doubling when cumulative exposure was increased from 1 week to .4 weeks. The temporal effect of exposure is also clear. The risk is highest in the month after exposure, but the effect of high-risk broad-spectrum antimicrobials remains for up to 6 months. 
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